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Effective immune responses to pathogens require the activation and differentiation of both innate 
and adaptive lymphocytes, such as innate lymphoid cells (ILCs) and T cells, respectively. ILCs 
consist of distinct helper-like subsets representing innate versions of CD4+ T helper subsets, whereas 
natural killer cells represent the innate counterpart of CD8+ cytotoxic T cells. By producing effector 
cytokines, T helper subsets and helper-like ILCs are also involved in the pathogenesis of many in-
flammatory diseases. Strikingly, the development of ILCs and T cells seems to depend on a shared 
transcriptional network. For example, GATA3 and Tcf7, which play essential roles during T cell 
development, are also indispensable for the development of multiple ILC subsets. Bcl11b is another 
critical component of a T cell lineage fate-specifying transcriptional network. In this issue, Yu et 
al. and Walker et al. independently describe the role of Bcl11b in specifying ILC2 development.
One would have expected that, similar to GATA3 and Tcf7, Bcl11b would be critical for the development of multiple ILC 
lineages. However, the two papers in this issue report that Bcl11b appears to be essential for ILC2 development only. Conse-
quently, Bcl11b deficiency leads to impaired immune responses to either papain treatment, influenza virus infection (Yu et al.), 
or Nippostrongylus brasiliensis helminth infection, without affecting the ability of mice to clear bacterial Citrobacter rodentium 
infection (Walker et al.). The authors show that Bcl11b is expressed in mature ILC2s as well as in a subset of Id2+ common 
helper-like innate lymphoid progenitors (ChILPs); Walker et al. but not Yu et al. also show that a proportion of other mature 
ILC subsets, such as CCR6 ILC3s, express Bcl11b. The discrepancy in Bcl11b expression by mature ILC3s between these two 
studies has not been resolved. Nevertheless, the Bcl11b-expressing ChILPs only give rise to ILC2s but not other ILCs, suggesting 
that the previously identified ChILPs contain a mixture of distinct committed ILC progenitors. This is consistent with another 
report in Nature suggesting that within the ChILP compartment, the PLZF+ progenitors are largely committed to specific ILC 
subsets and fail to generate lymphoid tissue inducers, which represent another subset of ChILP-derived ILCs.
Both reports also show that Bcl11b-expressing ILC2 progenitors express high levels of GATA3. However, other studies have 
reported that GATA3hi progenitors also give rise to other ILCs. In addition, GATA3 is constantly required for the maintenance of 
ILC2s, whereas inducible deletion of Bcl11b in mature ILC2s does not result in loss of functional ILC2s. Thus, Bcl11b either 
functions independently of GATA3 or collaborates with GATA3 during ILC2 development, but the detailed mechanism requires 
further investigation. Moreover, it is not known whether Bcl11b is critical for ILC2 development in humans.
It is intriguing that Bcl11b, which is 
critical for the development of all T cell 
subsets, appears to be dispensable for the 
development of ILC1s and ILC3s. Does 
this mean that T cells have preferentially 
adopted the ILC2 transcriptional pro-
gram during their early development in 
the thymus? If so, one would predict 
that T cell progenitors, particularly 
CD4CD8 thymocytes, might display 
certain features of ILC2s. This idea is 
consistent with the notion that T cells 
carry an endogenous Th2-prone pro-
gram that makes Th2 lymphocyte dif-
ferentiation a default cellular fate.
The studies of Yu et al. and Walker 
et al. not only identify Bcl11b as an 
ILC2 lineage-specifying factor, they also provide important general insights into the mechanisms of ILC development. Further-
more, this work raises the possibility that dysregulation of Bcl11b in ILC progenitors may contribute to human diseases involving 
ILC2 function.
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Bcl11b dr ives the birth of ILC2 innate lymphocytes
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Scheme of helper-like innate lymphoid cell (ILC) development. LTi: hematopoietic lymphoid tissue 
inducer lineage.
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Inflammation on the move
The mechanisms regulating wound injury and tissue repair involve complex enzymatic cascades 
and inflammatory processes, and new components are still being discovered. In this issue, 
Doni et al. report that the innate immune pattern recognition molecule (PRM), pentraxin 3 
(PTX3), has a novel and nonredundant role in the orchestration of tissue repair and remodeling 
during wound healing.
The innate immune system is equipped with an array of PRMs that detect conserved 
microbial motifs and mobilize early defense against foreign invaders. This pattern recognition 
system is multifunctional and can also detect endogenous alarmins that are released from 
damaged tissue. Detection of alarmins, such as extracellular matrix components and nucleic 
acids, is known to facilitate wound-healing reactions, in part through the induction of 
inflammation. PTX3 is a secreted, fluid-phase PRM that is rapidly produced by stromal and myelomonocytic cells. Its functions 
include opsonization, regulation of the complement cascade, and antimicrobial resistance, among others.
Using four different models of tissue damage (including skin damage and liver and lung sterile tissue injury), the authors showed that 
PTX3 deficiency caused marked alterations in wound healing, including excessive fibrin accumulation, enhanced collagen deposition, 
epithelial hyperplasia, and defective formation of mature tissue. Interestingly, PTX3 expression was associated with wound-healing cells 
such as macrophages within the lesion, suggesting a role for this glycoprotein in tissue remodeling. Consistent with this theory, Ptx3/ 
macrophages were less efficient at degrading fibrin matrix in vitro. Fibrin is a provisional extracellular matrix protein that is transiently 
deposited after tissue injury, but must be degraded for proper tissue remodeling and scar formation to occur.
To understand the link between 
PTX3 and fibrin matrix degradation, the 
authors conducted an elegant series of 
experiments involving tissue acidification 
showing that PTX3 serves as a molecular 
bridge between fibrin and plasminogen 
and promotes fibrinolysis. So, PTX3 ap-
pears to have an important role in fibrin 
breakdown, and tissue acidification serves 
as the switch that promotes this wound-
healing activity following injury.
These data demonstrate that PRMs 
such as PTX3 can have different func-
tions that depend on the tissue milieu and the manner by which they are activated. In fact, another recently published study 
from this same group in Cell showed that PTX3 also has anti-oncogenic properties linked to its ability to quench complement 
activation and reduce tumor infiltration by macrophages. We now know that induction of this protein has the potential to accelerate 
wound healing, ward off microbes, and suppress tumor growth. Given its ability to coordinate such diverse immune activities, 
PTX3 is a relevant and interesting target for therapeutic manipulation in damaged tissue as well as in a variety of diseases. Future 
avenues of research may uncover other unexpected roles for this fascinating molecule.
Bonavita, E., et al. 2015. Cell. 160:700–714.
Doni, A., et al. 2015. J. Exp. Med. http://dx.doi.org/10.1084/jem. 20141268
Hematoxylin-eosin and confocal images (green = fibrin; blue = nuclei) of fibrin in liver sections 
of wild-type (left) and Ptx3/ (right) mice. Blue arrowheads indicate deposits of fibrin in 
necroinflammatory areas in the lobular spaces 48 hours after chronic injury. Bars, 100 µm.
Rejane Rua and Dorian B. McGavern; National Institute of Neurological Disorders and Stroke, National Institutes of Health: mcgavernd@ninds.nih.gov
Inflammation is a major cause of morbidity, as illustrated by debilitating conditions such as rheumatoid arthritis and 
inflammatory bowel diseases. IL-1b and TNF are key mediators of inflammation, and agents that neutralize their 
effects have provided relief for millions of patients, but we may have yet more to discover about inflammation.
In this issue, Kim et al. show that mice with a hypomorphic mutation of Wdr1 (i.e., a mutation that 
results in underproduction of an otherwise normal product) develop inflammation caused by IL-18.
This is interesting for several reasons. To the cell biologist, Wdr1 is a protein that interacts with fila-
mentous actin. It is the murine homologue of human actin-interacting protein 1 (AIP1). The dynamics 
of cellular actin is crucial in cell biology and underlies fundamental cellular functions such as cell division, 
movement, and phagocytosis. Actin oscillates between filamentous actin and soluble actin. Cofilin binds 
Insight from 
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Pentraxin 3 innately preps damaged tissue for wound healing
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filamentous actin and severs the filaments, 
causing these to dissemble, yielding 
soluble actin. Wdr1 in mice and AIP1 
in humans bind the cofilin/filamentous 
actin complex and energize cofilin’s 
ability to sever the filaments. Null mu-
tations of Wdr1 are embryonic lethal; 
mice with hypomorphic mutations of 
Wdr1 are viable but have thrombocy-
topenia and their neutrophils have 
crawling defects. These mice also de-
velop autoinflammation.
The inflammasome is to immunolo-
gists what actin is to cell biologists. In-
tracellular sensors, such as the NOD-like 
receptors (NLRs) and the absent in mel-
anoma 2 (AIM2)–like receptors (ALRs), 
sense damage or danger signals and re-
cruit ASC (apoptosis-associated speck-like 
protein containing a caspase recruitment 
domain). In this complex, ASC generates caspase-1 by proteolytic cleavage of procaspase-1. Caspase-1 in turn cleaves pro–IL-1b 
and pro–IL-18, generating the potent proinflammatory cytokines IL-1b and IL-18 that are secreted from the cell.
Kim et al. report on a significant amount of work involving a comprehensive analysis of this novel mouse model. They 
show that myeloid cells from hypomorphic Wdr1 mutants have more filamentous actin than wild-type mice with spontane-
ous activation of ASC and caspase-1; the cells generate huge amounts of IL-1b and IL-18 as expected. This points to a criti-
cal role for actin dynamics in controlling the inflammasome. Surprisingly, the mice suffer inflammation of cartilage tissue 
rather than a generalized inflammation, and the inflammation is caused not by the elevated IL-1b but by IL-18. Further-
more, monocytes and not macrophages, neutrophils, or dendritic cells are responsible for the production of IL-18. The 
authors observed massive infiltration of neutrophils, but it was monocytes that migrated to the tissue, produced IL-18 lo-
cally, and initiated the inflammation.
This study provides a cellular framework for understanding the role of IL-18 in inflammation. This is a novel and intriguing 
paper that implicates the actin-depolymerizing cofactor Wdr1 in the regulation of the pyrin inflammasome and IL-18 production by 
monocytes. These results add to the growing literature on the role of actin polymerization in inflammation and may have 
translational implications for the therapy of patients with autoinflammatory conditions.
Kim, M.L., et al. 2015. J. Exp. Med. http://dx.doi.org/10.1084/jem.20142384
Niels Borregaard, University of Copenhagen: borregaard@rh.dk
Inflammasomes assemble on filamentous actin and generate IL-1b and IL-18. Wdr1 accelerates 
dissolution of filamentous actin and of the inflammasome. Mice hypomorphic for Wdr1 have 
more filamentous actin and their monocytes generate IL-1b and IL-18. The mice develop 
inflammation of cartillage tissue driven by IL-18, not by IL-1b.
Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative disorder of B lympho-
cytes. It has an extremely variable clinical course. Some patients have a rather indolent 
course, whereas others are known to have a rapidly progressive disease. Most patients die 
from causes related to CLL that can be due to bone marrow failure, infection, or transformation 
to a high-grade lymphoma. Clinical stratification of CLL has revealed that a subset of 
patients with poor prognosis harbor cytogenetic alterations and lack mutations at the immuno-
globulin locus. Therefore, the development of additional molecular biomarkers for patients 
at high risk for early lethality from CLL could help direct their care toward enrollment in 
clinical trials of promising experimental approaches such as inhibitors of BCL2 or BCR 
signaling or CD19 chimeric antigen receptor T cells (which have been shown to eradicate 
CLL in patients who have failed other approaches). In this issue, Mansouri et al. report that somatic mutations in the NFKBIE 
gene occur in 7% of poor prognosis patients, and this may be a common mechanism contributing to disease progression by 
sustaining the survival of malignant CLL cells.
Augmenting NF-kB in poor-r isk CLL: A general paradigm  
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The NF-kB pathway is ubiquitously activated in 
CLL cells by cell surface receptor signaling cascades 
through the B cell receptor and Toll-like receptors, 
so this identification of additional mutational events 
that reinforce NF-kB signaling appeared biochemi-
cally redundant. NFKBIE encodes the IkB protein, 
a potent and seemingly stoichiometric inhibitor of 
the IkB kinase (IKK) in CLL cells as demonstrated 
by Mansouri et al. Surprisingly, even partial deple-
tion of NFKBIE with RNA interference in cell cul-
ture was sufficient to activate IKK and promote 
NF-kB transcriptional activation, consistent with 
the findings that the NFKBIE mutations are 
heterozygous in CLL samples and that these samples 
had modest increases in NF-kB signaling. Whether 
the most recurrent NFKBIE mutation identified in 
this work (a 4-bp deletion in exon 1 that resulted in 
a frame shift and potentially expressed truncated 
protein) has neomorphic oncogenic functions besides the inability to inhibit IKK remains unknown.
More broadly, the finding of heterozygous NFKBIE mutations as a marker of poor prognosis raises the possibility that 
similar mutations or heterozygous loss of NFKBIE caused by genetic deletion or epigenetic silencing may also further 
sculpt NF-kB signaling and thereby promote the progression of more common malignancies. Unfortunately, most of the 
publicly available tumor genomes include a significant amount of contaminating normal cells, and therefore haploid loss 
of NFKBIE may not be appreciated. Single nuclei sequencing of neoplastic cells isolated freshly from tumors will address 
this and other issues of potential haploidy in cancer by unambiguously determining the cancer genome and concurrent 
genetic events. For CLL patients, the finding of the NFKBIE mutations in high-risk patients refocuses our attention on 
developing NF-kB inhibitors to use in tandem with other approaches and for considering experimental clinical trials for 
such patients.
Mansouri, L., et al. 2015. J. Exp. Med. http://dx.doi.org/10.1084/jem.20142009
Heterozygous gene dosage for NFKBIE is sufficient to disrupt NF-kB regulation. 
Fluorescent microscope images of the interaction between IkBe and the 
transcription factor p65 in cells from CLL patients that are either wild type for 
NFKBIE (left) or heterozygous for NFKBIE deleted (right). Blue color indicates 
cell nuclei; each red dot represents a single interaction.
David Tuveson, Cancer Center at Cold Spring Harbor Laboratory: dtuveson@cshl.edu 
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